The human HCC cells were maintained in
DMEM (Invitrogen, Grand Island, NY) with 10% fetal bovine serum (FBS), 1% Glutamine, and 1% penicillin/streptomycin.
NK-92MI cells (ATCC, Manassas, VA) were maintained in
α-MEM (Invitrogen) with 0.2 mM inositol, 0.1 mM 2-mercaptoethanol, 0.02 mM folic acid, horse serum to a final concentration of 12.5% and FBS to a final concentration of 12.5% based on ATCC guidelines. All cell lines were cultured ina5%(v/v) CO2 humidified incubator at 37 °C The
SK-Hep1 (ATCC, Manassas, VA) and
SNU423 (ATCC, Manassas, VA) AR stable transfectants were established based on a previous procedure [14 (
link)]. Cisplatin (479306), MG132 (M8699) and Cycloheximide (CHX, 227048) were purchased from Sigma.
To generate AR knock-down stable clones of
SK-Hep1 (ATCC, Manassas, VA) and
SNU423 cells (ATCC, Manassas, VA), HEK-293T cells were transfected with lentiviral vectors, pLKO1-sh-AR/pLKO1-scr, with the psAX2 packaging plasmid, and pMD2G envelope plasmid for 48 hrs to obtain the lentivirus supernatant, which was frozen at −80 °C for later use.
For the luciferase reporter assay, cells were transfected using
Lipofectamine 3000 (Invitrogen) reverse transfection protocol, according to the manufacturer's instructions. See
Supplemental data for detailed sequence information.
Shi L., Lin H., Li G., Sun Y., Shen J., Xu J., Yeh S., Cai X, & Chang C. (2016). Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. Cancer letters, 373(1), 45-56.